/>

Saturday, December 29, 2018

NEWS 29 DEC 2018

NEWS FROM USA

505 (b) 2s in pipeline

Tadalafil Sublingual Tablets (Adamis Pharma): Adamis pharama submits NDA application to the USFDA for its fast dissolving sublingual tadalafil tablets for the treatment of erectile dysfunction.

 

Dexmedetomidine Sublingual film (Bioxcel Therapetics): The U.S. FDA has granted Fast Track Designation for its investigational drug BXCL501 in the treatment of acute agitation

 

NEW GENERICS LAUNCHES IN US

 DRUG

COMPANY

Corresponding RLD

Annual sales quoted in press release as per IQVIA

Press Release

Pimecrolimus cream 1%

Teva Pharma

Elidel

218.4 Mn USD

Link

         

ANDA Approvals                                                  

Approval Date

Drug Product

ANDA

Sponsor

Corresponding RLD

Number Of Other Approved Generics

26 Dec 2018

Griseofulvin, Ultramicrosize Tablets

Sandoz 

Gris-Peg (Valeant)

Two (Mountain, Sigmapharm)

26 Dec 2018

Azithromycin Tablets

Bionpharma 

Zithromax (Pfizer)

Eight

26 Dec 2018

Clobetasol Propionate Cream

Amneal Pharms 

N/A

Ten

27 Dec 2018

Cinacalcet Hydrochloride Tablets

Watson Labs 

Sensipar (Amgen)

Seven

27 Dec 2018

Octreotide Acetate Injection

Usv North 

Sandostatin (Novartis)

Six

27 Dec 2018

Pimecrolimus Cream

Actavis 

Elidel (Valeant)

None

27 Dec 2018

Metformin Hydrochloride ER Tablets

Qingdao Baheal 

Fortamet (Andrx Labs)

Four

27 Dec 2018

Clofarabine Solution

Hospira 

Clolar (Genzyme)

Seven

29 Dec 2018

Clindamycin Phosphate And Benzoyl Peroxide Gel

Zydus

Duac (Stiefel)

Three

Highlighted product indicates first generic approval for the corresponding RLD.

 

Tentative ANDA Approvals 

Approval Date

Drug

Company

26 Dec 2018

Esomeprazole Magnesium; Naproxen

Dr Reddys 

26 Dec 2018

Aripiprazole

Pharmtak 

26 Dec 2018

Aripiprazole

Pharmtak 

27 Dec 2018

Pregabalin

Aurobindo 

27 Dec 2018

Pregabalin

Cadila 

 

NEWS RELATED TO GENERIC PATENT LITIGATION

Methylphenidate XR-ODT (Cotempla XR-ODT): Neos Therapeutics Announces Settlement with Teva on Cotempla XR-ODT Patent Litigation

If you have any query/suggestion then please write us at pharmacaption@gmail.com

                                                                                                                     

 

 

 

 

                                                                

No comments:

Post a Comment